Global Genetic Disorders Partnering Deal Trends, Players and Financials 2010-2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Genetic disorders Partnering 2010-2017: Deal trends, players and financials" report to their offering.

Global Genetic Disorders Partnering 2010 to 2017 provides the full collection of Genetic Disorders disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Report scope:

  • Trends in Genetic Disorders dealmaking in the biopharma industry since 2010
  • Analysis of Genetic Disorders deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Genetic Disorders deal contract documents
  • Comprehensive access to over 3500 Genetic Disorders deal records
  • The leading Genetic Disorders deals by value since 2010
  • Most active Genetic Disorders dealmakers since 2010

In Global Genetic Disorders Partnering 2010 to 2017, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in Genetic Disorders dealmaking

Chapter 3 -Financial deal terms for Genetic Disorders partnering

Chapter 4 - Leading Genetic Disorders deals and dealmakers

Chapter 5 - Genetic Disorders contract document directory

Chapter 6 - Genetic Disorders dealmaking by therapeutic target

For more information about this report visit http://www.researchandmarkets.com/research/gh3t6d/global_genetic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals